Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease
Nephrology Dialysis Transplantation, 05/03/2012
Clinical Article
Navaneethan SD et al. – Serum triglyceride ≥200 mg/dL was independently associated with all–cause mortality in Stage 3 and Stage 4 chronic kidney disease (CKD) patients aged <65 years but not among patients of age ≥65 years. Future studies should confirm these findings and examine the mechanisms that may explain these associations.
Methods- Patients with Stage 3 and Stage 4 CKD (estimated glomerular filtration rate 15–59 mL/min/1.73 m2) who had serum triglycerides measured prior to being classified as CKD were included.
- The authors examined the associations of serum triglyceride levels with all–cause mortality among 25641 Stage 3 and Stage 4 CKD patients using Cox proportional hazard models and Kaplan–Meier survival curves.
- In the Cox model, after adjusting for relevant covariates including other lipid parameters, serum triglyceride level 150–199 mg/dL was not associated with death [hazard ratio (HR) 1.00, 95% confidence interval (95% CI) 0.92–1.10] relative to serum triglyceride <150 mg/dL while serum triglyceride ≥200 mg/dL was associated with a 11% increased hazard for death (95% CI 1.01–1.22).
- Age modified the association between serum triglyceride levels ≥200 mg/dL and mortality with patients <65 years having a 38% higher hazard for death (95% CI 1.15–1.65) and ≥65 years with no increased risk for death (HR 0.97, 95% CI 0.88–1.08, P for interaction <0.001).
- When serum triglycerides were examined as a continuous log–transformed variable, similar associations with mortality were noted.
